Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Head & Neck 1Endocrine 1Dermatologic 1

Conditions

Carcinoma, Neuroendocrine 2Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Small Cell Lung Carcinoma 1Neuroendocrine Tumors 1Nasopharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1Mesothelioma, Malignant 1Lung Neoplasms 1Gastro-enteropancreatic neuroendocrine tumor 1Carcinoma, Merkel Cell 1Adenoma, Islet Cell 1Adenocarcinoma, Mucinous 1

Interventions

Everolimus 6Sunitinib 3Octreotide 3cabozantinib 2Specimen Handling 2Magnetic Resonance Spectroscopy 2Leucovorin 2Injections 2Fluorouracil 2Capecitabine 2Bevacizumab 2recombinant interferon alpha 2b-like protein 1pentetreotide 1pasireotide 1motesanib diphosphate 1lanreotide 1ibrutinib 1ganitumab 1gallium Ga 68 dotatate 1fludarabine phosphate 1belzutifan 1batifiban 1atezolizumab 1abemaciclib 1X-Rays 1Thalidomide 1Temozolomide 1Streptozocin 1Sorafenib 1Phantoms, Imaging 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenoma, Islet Cell × Disulfides × Endocrine × Clear all
NCT03074513 2026-03-11

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
133 enrolled
DermatologicEndocrineHead & NeckOther solid neoplasmThoracic

Nasopharyngeal Carcinoma, Mesothelioma, Malignant, Adenocarcinoma, Mucinous, Adenoma, Islet Cell, Nasopharyngeal Neoplasms, Carcinoma, Merkel Cell, Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡